<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04258735</url>
  </required_header>
  <id_info>
    <org_study_id>2019-05-157</org_study_id>
    <nct_id>NCT04258735</nct_id>
  </id_info>
  <brief_title>Genetic Characteristics of Metastatic Breast Cancer Patients</brief_title>
  <official_title>Genetic Characteristics of Metastatic Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Genomic analysis for metastatic breast cancer(MBC) patients

        -  Participant (Inclusion criteria)

             1. Patients who diagnosed metastatic/stage IV breast cancer

             2. Patients who were not received treatment for metastatic breast cancer on palliative
                setting

        -  Process

           (1) Tissue/ Blood sample

        -  At diagnosis, MBC tissue / blood sample (20cc) will be obtained.

        -  At disease progression after 1st line treatment for MBC, blood sample (20cc) will be
           obtained (tissue; optional)

           (2) WES, RNASeq, ctDNA, Exosome

        -  We will analyze genomic characteritics using WES, RNASeq, ctDNA, Exosome.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 17, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Genomic profiling of MBC patients</measure>
    <time_frame>60 months</time_frame>
    <description>Gemetic alteration frequency, the association between genetic alteration and survival</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Metastatic breast cancer cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Metastatic breast cancer with genetic tests including WES, RNASeq, ctDNA and exosome</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Genomic analysis</intervention_name>
    <description>WES, RNASeq, ctDNA, Exosome</description>
    <arm_group_label>Metastatic breast cancer cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who diagnosed ad metastatic breast cancer

          -  Patients who were not received treatment on palliative setting

        Exclusion Criteria:

          -  Patients who did not agree this study

          -  Patients who did not have any pathologic specimen at MBC diagnosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Young-Hyuck Im, MD,PhD</last_name>
    <phone>82-2-3410-3459</phone>
    <email>yh00.im@samsung.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ji-Yeon Kim, MD</last_name>
    <phone>82-2-3410-3459</phone>
    <email>jyeon25.kim@samsung.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Samsung Medical Center, Sungkyunkwan University School of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Hyuck Im, MD, PhD</last_name>
      <phone>+82-2-3410-3445</phone>
      <email>yh00.im@samsung.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 23, 2019</study_first_submitted>
  <study_first_submitted_qc>February 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2020</study_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Samsung Medical Center</investigator_affiliation>
    <investigator_full_name>Young-Hyuck Im</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

